Education
About Us
Working with TipRanks
Follow Us
Grifols, SA (GB:0RDV)
:0RDV
0RDV Stock Chart & Stats
Day’s Range― - ―
52-Week Range€5.62 - €9.71
Previous CloseN/A
Volume658.00
Average Volume (3M)74.68K
Market Cap
€7.87B
Enterprise Value€15.99B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)21.0
Beta1.71
Next Earnings
Nov 06, 2025EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding261,425,100
10 Day Avg. Volume173,576
30 Day Avg. Volume74,678
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.25Price Target Upside62.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Grifols News
0RDV FAQ
What was Grifols, SA’s price range in the past 12 months?
Grifols, SA lowest share price was €5.62 and its highest was €9.71 in the past 12 months.
What is Grifols, SA’s market cap?
Grifols, SA’s market cap is €7.87B.
When is Grifols, SA’s upcoming earnings report date?
Grifols, SA’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.
How were Grifols, SA’s earnings last quarter?
Grifols, SA released its earnings results on Jul 29, 2025. The company reported €0.172 earnings per share for the quarter, missing the consensus estimate of €0.193 by -€0.021.
Is Grifols, SA overvalued?
According to Wall Street analysts Grifols, SA’s price is currently Undervalued.
Does Grifols, SA pay dividends?
Grifols, SA does not currently pay dividends.
What is Grifols, SA’s EPS estimate?
Grifols, SA’s EPS estimate is 0.24.
How many shares outstanding does Grifols, SA have?
Grifols, SA has 261,425,100 shares outstanding.
What happened to Grifols, SA’s price movement after its last earnings report?
Grifols, SA reported an EPS of €0.172 in its last earnings report, missing expectations of €0.193. Following the earnings report the stock price went down -0.342%.
Which hedge fund is a major shareholder of Grifols, SA?
Currently, no hedge funds are holding shares in GB:0RDV
Grifols Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€15.25 (62.41% Upside)
€15.25 (62.41% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.11%
12-Months-Change
Fundamentals
Return on Equity
5.53%
Trailing 12-Months
Asset Growth
-11.32%
Trailing 12-Months
Company Description
Grifols, SA
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 78% of sales in 2019. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 14% of revenue following the Novartis and Hologic deals.
Technical Analysis
Almirall
―
Faes Farma
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
Ownership Overview
―
Insiders
3.46%
Mutual Funds
0.02% Other Institutional Investors
94.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---